{"id":88060,"date":"2026-06-19T20:20:41","date_gmt":"2026-06-19T20:20:41","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/88060\/"},"modified":"2026-06-19T20:20:41","modified_gmt":"2026-06-19T20:20:41","slug":"fda-approves-first-generic-version-of-roches-flu-drug-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/88060\/","title":{"rendered":"FDA approves first generic version of Roche&#8217;s flu drug"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">June 17 (Reuters) &#8211; The U.S. Food and Drug Administration approved the first generic \u200cversion of Roche&#8217;s Xofluza, a single-dose \u200cflu medicine for certain patients aged five years and \u200bolder, the regulator said on Wednesday.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The approval of Norwich Pharmaceuticals&#8217; generic drug comes ahead of the flu season.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">It can be used to treat \u200cuncomplicated flu \u2060in patients who have had symptoms for no more than 48 hours, \u2060including those who are otherwise healthy or at high risk of flu-related complications, the FDA \u200bsaid.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The drug \u200bcan also be \u200bused to help \u200cprevent flu after contact with an infected person, the agency added.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Baloxavir marboxil, marketed as Xofluza by Roche, was first approved by the FDA in 2018 and is taken as \u200ca single oral dose. It \u200bis marketed in the \u200bU.S. by trhe \u200bcompany&#8217;s Genentech unit.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The most common \u200cside effects of baloxavir marboxil \u200binclude diarrhea, \u200bbronchitis, nausea, sinusitis and headache. It carries warnings such as increased incidence of \u200btreatment-emergent resistance \u200cin patients less than five years of \u200bage.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">(Reporting by Kunal Das in Bengaluru; \u200bEditing by Joyjeet Das)<\/p>\n","protected":false},"excerpt":{"rendered":"June 17 (Reuters) &#8211; The U.S. Food and Drug Administration approved the first generic \u200cversion of Roche&#8217;s Xofluza,&hellip;\n","protected":false},"author":2,"featured_media":88061,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[44727,11767,9806,44728,134],"class_list":["post-88060","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-flu-season","tag-food-and-drug-administration","tag-generic-version","tag-norwich-pharmaceuticals","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116778632956097551","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/88060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=88060"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/88060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/88061"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=88060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=88060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=88060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}